PBAC's latest decision on Perfluorohexyloctane: Recommended with restriction (2018). Considered for Treatment of severe dry eye syndrome in patients who are sensitive to preservatives in multi-dose eye drops.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2018
Submissions
1
2018 → 2018
Eligible population
Patients with severe dry eye syndrome who are sensitive to preservatives in multi-dose eye drops.
Therapy area
Ophthalmology
Line of therapy
Not applicable
Evidence base
Single-arm
Primary endpoint
Other
Key trials
NT-001, NT-002
Comparator
soy lecithin
Economic model
Cost-minimisation
ICER note
Minor submission with cost comparison only; no formal ICER calculated. Economic analysis presented cost comparison across PBS-listed preservative-free ocular lubricants.